MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Search

Twist Bioscience Corp

Closed

SectorHealthcare

47.72 -2.27

Overview

Share price change

24h

Current

Min

47.31

Max

47.94

Key metrics

By Trading Economics

Income

-3.4M

-31M

Sales

4.7M

104M

Profit margin

-29.419

Employees

979

EBITDA

-3.2M

-24M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+10.16% upside

Dividends

By Dow Jones

Next Earnings

4 May 2026

Market Stats

By TradingEconomics

Market Cap

536M

3.1B

Previous open

49.99

Previous close

47.72

News Sentiment

By Acuity

50%

50%

185 / 348 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

10 Apr 2026, 17:04 UTC

Major Market Movers

FDA Rejects Replimune's Melanoma Drug for a Second Time

11 Apr 2026, 00:00 UTC

Earnings
Acquisitions, Mergers, Takeovers

Big Yachts, Big Bucks -- Barrons.com

10 Apr 2026, 21:55 UTC

Acquisitions, Mergers, Takeovers

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 Apr 2026, 21:01 UTC

Earnings

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 Apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10 Apr 2026, 20:50 UTC

Market Talk
Major News Events

Basic Materials Roundup: Market Talk

10 Apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 Apr 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 Apr 2026, 20:10 UTC

Acquisitions, Mergers, Takeovers

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 Apr 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10 Apr 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 Apr 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 Apr 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 Apr 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10 Apr 2026, 18:25 UTC

Market Talk
Major News Events

Precious Metals Finish With Weekly Gains -- Market Talk

10 Apr 2026, 18:05 UTC

Market Talk

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10 Apr 2026, 17:31 UTC

Market Talk
Major News Events

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10 Apr 2026, 17:26 UTC

Earnings

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10 Apr 2026, 17:10 UTC

Market Talk

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10 Apr 2026, 17:00 UTC

Major News Events

Construction Business Taking a Hit From Iran Conflict -- WSJ

10 Apr 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

10 Apr 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

10 Apr 2026, 16:12 UTC

Earnings

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10 Apr 2026, 16:11 UTC

Earnings

Partners Group: Traditional Programs Contributed $3.3B

10 Apr 2026, 16:10 UTC

Earnings

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10 Apr 2026, 16:10 UTC

Earnings

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10 Apr 2026, 16:10 UTC

Earnings

Partners Group 1Q New Client Demand $8.3B

10 Apr 2026, 16:09 UTC

Earnings

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10 Apr 2026, 15:54 UTC

Acquisitions, Mergers, Takeovers

Plenitude Completes Acquisition of Acea Energia

10 Apr 2026, 15:38 UTC

Market Talk

Global Energy Roundup: Market Talk

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

10.16% upside

12 Months Forecast

Average 53.8 USD  10.16%

High 58 USD

Low 50 USD

Based on 6 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

185 / 348 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat